Talking About Tumors

Chapter 3

Chapter 3: Lung / HNSCC / Immunotherapy / Cutaneous

Immune checkpoint inhibitors, melanoma, lung cancer, mesothelioma, and head and neck malignancies.

← Back to episode archive

S03 E01

The era of immune checkpoint inhibitors

Open episode on Buzzsprout

Show notes

Topics covered

  1. History of Immunotherapy
  2. Modern immune checkpoint inhibitors (ICIs)
  3. Unique considerations with ICIs
  4. Immune related adverse events and immortal time bias in observational studies
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Yadav K, Lewis RJ. JAMA. 2021;325(7):686-687. doi:10.1001/JAMA.2020.9151
  2. 2. Holstead RG et al. Melanoma Res. 2021;31(3):258-263. doi:10.1097/CMR.0000000000000736
  3. 3. Kartolo A et al. J Immunother. 2021;44(4):167-174. doi:10.1097/CJI.0000000000000360
  4. 4. Dolladille C et al. JAMA Oncol. 2020;6(6):865-871. doi:10.1001/JAMAONCOL.2020.0726
  5. 5. Mahmood SS et al. J Am Coll Cardiol. 2018;71(16):1755-1764. doi:10.1016/J.JACC.2018.02.037
  6. 6. Coley WB. Proc R Soc Med. 1910;3(Surg Sect):1. doi:10.1177/003591571000301601
  7. 7. Larkin J et al. NEJM. 2019;381(16):1535-1546. doi:10.1056/NEJMOA1910836
  8. 8. Wolchok JD et al. Lancet Oncol. 2010;11(2):155-164. doi:10.1016/S1470-2045(09)70334-1
  9. 9. Hodi FS et al. NEJM. 2010;363(8):711-723. doi:10.1056/NEJMOA1003466/SUPPL_FILE
  10. 10. Brahmer J et al. JCO. 2018;36(17):1714-1768 doi:10.1200/JCO.2017.77.6385
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

S03 E02

Localized Melanoma

Open episode on Buzzsprout

Show notes

Topics covered

  1. Background, staging and work-up of regional melanoma
  2. Evidence for adjuvant and neoadjuvant immunotherapy
  3. Adjuvant BRAF/MEK inhibitor
  4. Considerations for stage IIB/IIC disease
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Patel SP et al. NEJM. 2023;388(9):813-823. doi:10.1056/NEJMOA2211437
  2. 2. Weber J et al. NEJM. 2017;377(19):1824-1835. doi:10.1056/NEJMOA1709030
  3. 3. Eggermont AMM et al. NEJM. 2018;378(19):1789-1801. doi:10.1056/NEJMOA1802357
  4. 4. Lao CD. Am Soc Clin Oncol Educ Book. 2022;42(42):1-7. doi:10.1200/EDBK_351153
  5. 5. Faries MB et al. NEJM. 2017;376(23):2211-2222. doi:10.1056/NEJMOA1613210
  6. 6. Morton DL et al. NEJM. 2014;370(7):599-609. doi:10.1056/NEJMOA1310460
  7. 7. Welch HG et al. NEJM. 2021;384(1):72-79. doi:10.1056/NEJMSB2019760
  8. 8. Michielin O et al. Ann Oncol. 2019;30(12):1884-1901. doi:10.1093/ANNONC/MDZ411
  9. 9. Luke JJ et al. Lancet. 2022;399(10336):1718-1729. doi:10.1016/S0140-6736(22)00562-1
  10. 10. Long G V et al. NEJM. 2017;377(19):1813-1823. doi:10.1056/NEJMOA1708539
  11. 11. Dummer R et al. NEJM. 2020;383(12):1139-1148. doi:10.1056/NEJMOA2005493
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

S03 E03

Metastatic Melanoma

Open episode on Buzzsprout

Show notes

Topics covered

  1. Patterns of recurrence and approach to stage IV disease
  2. Immunotherapy and BRAF/MEK considerations
  3. Cross trial comparisons
  4. Later line and emerging therapies for advanced melanoma
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Atkins MB et al. J Clin Oncol. 2023;41(2):186-197. doi:10.1200/JCO.22.01763
  2. 2. Robert C et al. NEJM. 2019;381(7):626-636. doi:10.1056/NEJMOA1904059
  3. 3. Lebbé C et al. J Clin Oncol. 2019;37(11):867-875. doi:10.1200/JCO.18.01998
  4. 4. Wolchok JD et al. J Clin Oncol. 2022;40(2):127-137. doi:10.1200/JCO.21.02229
  5. 5. Larkin J et al. NEJM. 2015;373(1):23-34. doi:10.1056/NEJMOA1504030
  6. 6. Nathan P et al. NEJM. 2021;385(13):1196-1206. doi:10.1056/NEJMOA2103485
  7. 7. Sarnaik AA et al. J Clin Oncol. 2021;39(24):2656-2666. doi:10.1200/JCO.21.00612
  8. 8. Tawbi HA et al. NEJM. 2022;386(1):24-34. doi:10.1056/NEJMOA2109970
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

S03 E04

Overview of Lung Cancer

Open episode on Buzzsprout

Show notes

Topics covered

  1. Presentation and Work-up
  2. Staging and how to memorize staging algorithms
  3. SVC Syndrome, an oncologic emergency
  4. Variations by histology and molecular mutations
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

    Disclosure and tags

    Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

    Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

    S03 E05

    NSCLC metastatic without driver mutations

    Open episode on Buzzsprout

    Show notes

    Topics covered

    1. Evidence to support platinum doublets
    2. The tale of pemetrexed
    3. Immune checkpoint inhibitors alone and in combination
    4. Second Line, approach in progression
    References and source notes

    As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

    DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

    Uptodate.com Waltham, MA: Wolters Kluwer.

    1. 1. Paz-Ares L et al. Lancet Oncol. 2021;22(2):198-211. doi:10.1016/S1470-2045(20)30641-0
    2. 2. Hellmann MD et al. NEJM. 2019;381(21):2020-2031. doi:10.1056/NEJMOA1910231
    3. 3. Socinski MA et al. J Thorac Oncol. 2021;16(11):1909-1924. doi:10.1016/J.JTHO.2021.07.009
    4. 4. Reck M et al. NEJM. 2016;375(19):1823-1833. doi:10.1056/NEJMOA1606774
    5. 5. Paz-Ares L et al. NEJM. 2018;379(21):2040-2051. doi:10.1056/NEJMOA1810865
    6. 6. Gandhi L et al. NEJM. 2018;378(22):2078-2092. doi:10.1056/NEJMOA1801005
    7. 7. Scagliotti G et al. Oncologist. 2009;14(3):253-263. doi:10.1634/THEONCOLOGIST.2008-0232
    8. 8. Paz-Ares L et al. Lancet Oncol. 2012;13(3):247-255. doi:10.1016/S1470-2045(12)70063-3
    9. 9. Paz-Ares LG et al. JCO. 2013;31(23):2895-2902. doi:10.1200/JCO.2012.47.1102
    10. 10. Scagliotti GV et al. JCO. 2008;26(21):3543-3551. doi:10.1200/JCO.2007.15.0375
    11. 11. Delbaldo C et al. JAMA. 2004;292(4):470-484. doi:10.1001/JAMA.292.4.470
    12. 12. Ardizzoni A et al. J Natl Cancer Inst. 2007;99(11):847-857. doi:10.1093/JNCI/DJK196
    13. 13. Temel JS et al. NEJM. 2010;363(8):733-742. doi:10.1056/NEJMOA1000678
    Disclosure and tags

    Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

    Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

    S03 E06

    Driver Mutations in Advanced NSCLC

    Open episode on Buzzsprout

    Show notes

    Topics covered

    1. EGFR inhibitors
    2. ALK inhibitors
    3. Less common molecular targets
    4. Role of KRAS inhibitors and evidence for sotorasib
    References and source notes

    As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

    DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

    Uptodate.com Waltham, MA: Wolters Kluwer.

    1. 1. de Langen AJ et al. The Lancet. 2023;401(10378):733-746. doi:10.1016/S0140-6736(23)00221-0
    2. 2. Wolf J et al. NEJM. 2020;383(10):944-957. doi:10.1056/NEJMOA2002787
    3. 3. Felip E et al. Annals of Oncology. 2021;32(5):620-630. doi:10.1016/j.annonc.2021.02.012
    4. 4. Cho BC et al. J Thorac Oncol. 2017;12(9):1357-1367. doi:10.1016/J.JTHO.2017.07.005
    5. 5. Peters S et al. NEJM. 2017;377(9):829-838. doi:10.1056/NEJMOA1704795
    6. 6. Solomon BJ et al. JCO. 2018;36(22):2251-2258. doi:10.1200/JCO.2017.77.4794
    7. 7. Solomon BJ et al. NEJM. 2014;371(23):2167-2177. doi:10.1056/NEJMOA1408440
    8. 8. Yang JCH et al. Lancet Oncol. 2015;16(2):141-151. doi:10.1016/S1470-2045(14)71173-8
    9. 9. Soria JC et al. NEJM. 2018;378(2):113-125. doi:10.1056/NEJMOA1713137
    10. 10. Ramalingam SS et al. NEJM. 2020;382(1):41-50. doi:10.1056/NEJMOA1913662
    11. 11. Zhang SS et al. Lung Cancer: Targets and Therapy. 2023;14:27. doi:10.2147/LCTT.S403461
    12. 12. Olivier T et al. Transl Oncol. 2023;28:101591. doi:10.1016/J.TRANON.2022.101591
    13. 13. Papadimitrakopoulou VA, et al. Ann Oncol. 2020;31(11):1536-1544. doi:10.1016/J.ANNONC.2020.08.2100
    14. 14. Fukuoka M et al. J Clin Oncol. 2011;29(21):2866-2874. doi:10.1200/JCO.2010.33.4235
    Disclosure and tags

    Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

    Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

    S03 E07

    (Neo)Adjuvant NSCLC

    Open episode on Buzzsprout

    Show notes

    Topics covered

    1. Considerations with surgery, radiation, rate of relapse
    2. Adjuvant chemotherapy
    3. Adjuvant immune checkpoint inhibition
    4. Emerging neoadjuvant trial
    References and source notes

    As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

    DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

    Uptodate.com Waltham, MA: Wolters Kluwer.

    1. 1. Spicer J et al. JCO. 2023;41(16_suppl):8521-8521. doi:10.1200/JCO.2023.41.16_SUPPL.8521
    2. 2. Wakelee H et al. NEJM. Published online June 3, 2023. doi:10.1056/NEJMOA2302983
    3. 3. Forde PM et al. NEJM. 2022;386(21):1973-1985. doi:10.1056/NEJMOA2202170
    4. 4. Winton T et al. NEJM. 2005;352(25):2589-2597. doi:10.1056/NEJMOA043623
    5. 5. Stewart et al. BMJ. 1995;311(7010):899-909. doi:10.1136/BMJ.311.7010.899
    6. 6. Arriagada R et al. NEJM. 2004;350(4):351-360. doi:10.1056/NEJMOA031644
    7. 7. Weerakkody Y. Lung cancer (staging - IASLC 8th edition). Radiopaedia.org. Published online January 12, 2017. doi:10.53347/RID-50570
    8. 8. Felip E et al. The Lancet. 2021;398(10308):1344-1357. doi:10.1016/S0140-6736(21)02098-5
    9. 9. Strauss GM et al. J Clin Oncol. 2008;26(31):5043-5051. doi:10.1200/JCO.2008.16.4855
    10. 10. Pignon JP et al. JCO. 2008;26(21):3552-3559. doi:10.1200/JCO.2007.13.9030
    Disclosure and tags

    Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

    Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

    S03 E08

    ADAURA Trial

    Open episode on Buzzsprout

    Show notes

    Topics covered

    1. Background on adjuvant EGFR therapy
    2. Discussion of initial and updated results
    3. Hazard Ratios and Context
    4. When crossover and access limit generalizability
    References and source notes

    As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

    DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

    Uptodate.com Waltham, MA: Wolters Kluwer.

    1. 1. Herbst et al. JCO. 2023;41(10):1830-1840. doi: 10.1200/JCO.22.02186
    2. 2. Wu et al. NEJM. 2023;383:1711-1723. doi:10.1056/NEJMoa2027071
    3. 3. Tsuboi et al. NEJM. 2023;389(2):137-147. doi: 10.1056/NEJMoa2304594
    4. 4. West and Gyawali. JAMA Oncol. 2021;7(5):677-678. doi:10.1001/jamaoncol.2020.6752 Gyawali and West. JCO. 2021;39(3):175-177. doi: 10.1200/JCO.20.01762 Prasad. Plenary Session. “ADAURA OS Results”. Podcast episode published June 8, 2023 Haslan and Prasad. Ann Oncol. 2018; 29(5):1079–1081. doi: 10.1093/annonc/mdy116 Tannock et al. JCO. 2023;41(15):2713-2717 doi: 10.1200/JCO.23.00280
    Disclosure and tags

    Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

    Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

    S03 E09

    Stage III NSCLC for the Medical Oncologist

    Open episode on Buzzsprout

    Show notes

    Topics covered

    1. Refresher on T+N staging for Stage III
    2. Evidence for concurrent chemoradiation
    3. PACIFIC Trial
    4. Encourage cessation regardless of stage of Lung Cancer
    References and source notes

    As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

    DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

    Uptodate.com Waltham, MA: Wolters Kluwer.

    1. 1. Ajani JA et al.. Ann Oncol. 2013;24(11):2844-2849. doi:10.1093/ANNONC/MDT339
    2. 2. Curran WJ et al. J Natl Cancer Inst. 2011;103(19):1452-1460. doi:10.1093/JNCI/DJR325
    3. 3. Vokes EE, et al. JCO. 2007;25(13):1698-1704. doi:10.1200/JCO.2006.07.3569
    4. 4. Dillman RO et al. NEJM. 1990;323(14):940-945. doi:10.1056/NEJM199010043231403
    5. 5. Daly ME et al. JCO. 2022;40(12):1356-1384. doi:10.1200/JCO.21.02528
    6. 6. Spigel DR et al. JCO. 2022;40(12):1301-1311. doi:10.1200/JCO.21.01308
    7. 7. Antonia SJ et al. NEJM. 2017;377(20):1919-1929. doi:10.1056/NEJMOA1709937
    8. 8. Senan et al. JCO. 2016;34(9):953-962. doi:10.1200/JCO.2015.64.8824
    Disclosure and tags

    Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

    Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

    S03 E10

    Small cell lung cancer

    Open episode on Buzzsprout

    Show notes

    Topics covered

    1. Background on SCLC
    2. Approach to treatment by stage
    3. Emerging discussion on prophylactic cranial irradiation
    4. Brief review of basket and umbrella trials
    References and source notes

    As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

    DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

    Uptodate.com Waltham, MA: Wolters Kluwer.

    1. 1. Trigo J et al. Lancet Oncol. 2020;21(5):645-654. doi:10.1016/S1470-2045(20)30068-1
    2. 2. O’Brien MER et al. J Clin Oncol. 2006;24(34):5441-5447. doi:10.1200/JCO.2006.06.5821
    3. 3. Rudin CM et al. J Clin Oncol. 2020;38(21):2369-2379. doi:10.1200/JCO.20.00793
    4. 4. Paz-Ares L et al. The Lancet. 2019;394(10212):1929-1939. doi:10.1016/S0140-6736(19)32222-6
    5. 5. Horn L et al NEJM. 2018;379(23):2220-2229. doi:10.1056/NEJMOA1809064
    6. 6. Lowenbraun S et al. Cancer. 1979;44:406-413. doi:10.1002/1097-0142
    7. 7. Hochstenbag M et al.. J Neurooncol. 2000;48(3):243-248. doi:10.1023/A:1006427407281
    8. 8. Meert AP et al. BMC Cancer. 2001;1(1):1-9. doi:10.1186/1471-2407-1-5/TABLES/4
    9. 9. Fried DB et al. J Clin Oncol. 2004;22(23):4785-4793. doi:10.1200/JCO.2004.01.178
    10. 10. Pignon JP et al. 2010;327(23):1618-1624. doi:10.1056/NEJM199212033272302
    11. 11. Warde P, Payne D. J Clin Oncol. 1992;10(6):890-895. doi:10.1200/JCO.1992.10.6.890
    12. 12. Wong AT et al. J Thorac Oncol. 2016;11(2):242-248. doi:10.1016/J.JTHO.2015.10.011
    13. 13. Lu C et al. Ther Innov Regul Sci. 2021;55(6):1145. doi:10.1007/S43441-021-00315-7
    Disclosure and tags

    Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

    Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

    S03 E11

    Mesothelioma and a bit of Large Cell Neuroendocrine Carcinoma

    Open episode on Buzzsprout

    Show notes

    Topics covered

    1. Presentation, and considerations for regional mesothelioma
    2. Systemic therapy options for advanced mesothelioma
    3. Corticosteroids for pemetrexed, paclitaxel and docetaxel
    4. A quick review on considerations for LCNEC
    References and source notes

    As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

    DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

    Uptodate.com Waltham, MA: Wolters Kluwer.

    1. 1. Peters S et al. Ann Oncol. 2022;33(5):488-499. doi:10.1016/j.annonc.2022.01.074
    2. 2. Baas P et al. Lancet. 2021;397(10272):375-386. doi:10.1016/S0140-6736(20)32714-8
    3. 3. Vogelzang NJ et al. J Clin Oncol. 2003;21(14):2636-2644. doi:10.1200/JCO.2003.11.136
    4. 4. Zalcman G, et al. Lancet. 2016;387(10026):1405-1414. doi:10.1016/S0140-6736(15)01238-6
    5. 5. Santoro A, et al. J Thorac Oncol. 2008;3(7):756-763. doi:10.1097/JTO.0B013E31817C73D6
    6. 6. Lindsay CR et al. Br J Cancer 2021;125(9):1210-1216. doi:10.1038/s41416-021-01407-9
    Disclosure and tags

    Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

    Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

    S03 E12

    Head and Neck Cancer – Background and adjuvant considerations

    Open episode on Buzzsprout

    Show notes

    Topics covered

    1. Anatomy, diagnostic work-up and staging
    2. Field cancerization
    3. Indications for adjuvant concurrent chemoradiation
    4. Evidence to support weekly cisplatin with concurrent radiation
    References and source notes

    As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

    DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

    Uptodate.com Waltham, MA: Wolters Kluwer.

    1. 1. Bernier J et al. Head Neck. 2005;27(10):843-850. doi:10.1002/HED.20279
    2. 2. Zevallos JP et al. Head Neck. 2021;43(1):108. doi:10.1002/HED.26465
    3. 3. Young A, Okuyemi OT. StatPearls. Published online January 12, 2023. Accessed October 30, 2023. https://www.ncbi.nlm.nih.gov/books/NBK563022/
    4. 4. Kiyota N et al. J Clin Oncol. 2022;40(18):1980-1990. doi:10.1200/JCO.21.01293
    5. 5. Sharma P et al. J Clin Oncol. 2022;40(16). doi: 10.1200/JCO.2022.40.16_suppl.6004
    6. 6. Cooper JS et al. NEJM. 2004;350(19):1937-1944. doi:10.1056/NEJMOA032646
    7. 7. Bernier J et al. NEJM. 2004;350(19):1945-1952. doi:10.1056/NEJMOA032641
    Disclosure and tags

    Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

    Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

    S03 E13

    Head and Neck Cancer – Locally advanced and metastatic

    Open episode on Buzzsprout

    Show notes

    Topics covered

    1. Role for definitive chemotherapy and radiation
    2. Controversy on induction chemotherapy
    3. Considerations for nasopharyngeal cancer
    4. Approach to metastatic HNSCC
    References and source notes

    As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

    DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

    Uptodate.com Waltham, MA: Wolters Kluwer.

    1. 1. Burtness B et al. J Clin Oncol. 2022;40(21):2321-2332. doi:10.1200/JCO.21.02198
    2. 2. Burtness B et al. Lancet. 2019;394(10212):1915-1928. doi:10.1016/S0140-6736(19)32591-7
    3. 3. Vermorken JB et al. NEJM 2008;359(11):1116-1127. doi:10.1056/NEJMOA0802656
    4. 4. Gibson MK et al. JCO. 2005;23(15):3562-3567. doi:10.1200/JCO.2005.01.057
    5. 5. Zhang L et al. Lancet. 2016;388(10054):1883-1892. doi:10.1016/S0140-6736(16)31388-5
    6. 6. Zhang Y et al. NEJM. 2019;381(12):1124-1135. doi:10.1056/NEJMOA1905287
    7. 7. Gau M et al. Oral Oncol. 2019;95:164-169. doi:10.1016/J.ORALONCOLOGY.2019.06.015
    8. 8. GT W, et al. NEJM. 1991;324(24):1685-1690. doi:10.1056/NEJM199106133242402
    9. 9. Lacas B et al. Radiother Oncol. 2021;156:281. doi:10.1016/J.RADONC.2021.01.013
    10. 10. Bourhis et al. JCO. 2004;22(14_suppl):5505-5505. doi:10.1200/JCO.2004.22.90140.5505
    11. 11. Gyawali B et al. Cancer Treat Rev. 2016;44:10-16. doi:10.1016/J.CTRV.2016.01.002
    12. 12. Forastiere AA et al. J Clin Oncol. 1992;10(8):1245-1251. doi:10.1200/JCO.1992.10.8.1245
    13. 13. Posner MR et al. NEJM. 2007;357(17):1705-1715. doi:10.1056/NEJMOA070956
    Disclosure and tags

    Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

    Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology